A
Avraham Yacobi
Researcher at Dole Food Company
Publications - 118
Citations - 6513
Avraham Yacobi is an academic researcher from Dole Food Company. The author has contributed to research in topics: Pharmacokinetics & Bioavailability. The author has an hindex of 30, co-authored 118 publications receiving 6370 citations. Previous affiliations of Avraham Yacobi include American Cyanamid & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Bioanalytical method validation--a revisit with a decade of progress.
Vinod P. Shah,Kamal K. Midha,John W. A. Findlay,Howard Hill,James D. Hulse,Iain J. McGilveray,Gordon McKay,Krys J. Miller,Rabindra Patnaik,Mark L. Powell,Alfred P. Tonelli,C. T. Viswanathan,Avraham Yacobi +12 more
TL;DR: The purpose of this report is to represent the progress in analytical methodologies over the last decade and assessment of the major agreements and issues discussed with regard to small molecules at both the conference and the workshop.
Journal ArticleDOI
Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies
Vinod P. Shah,Kamal K. Midha,Shrikant Dighe,Iain J. McGilveray,Jerome P. Skelly,Avraham Yacobi,Thomas Layloff,C. T. Viswanathan,C. Edgar Cook,R. D. McDowall,Kenneth A. Pittman,Sidney Spector +11 more
TL;DR: The report presents the assessment of the major agreements and issues discussed at the conference onAnalytical Methods Validation to provide guiding principles for validation of analytical methods used in bioavailability, bioequivalence, and pharmacokinetics studies in humans and animals.
Journal ArticleDOI
Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies
Vinod P. Shah,Kamal K. Midha,Shrikant Dighe,Iain J. McGilveray,Jerome P. Skelly,Avraham Yacobi,Thomas Layloff,C. T. Viswanathan,C. Edgar Cook,R. D. McDowall,Kenneth A. Pittman,Sidney Spector +11 more
TL;DR: The report presents the assessment of the major agreements and issues discussed at the conference on analytical methods validation and provides guiding principles for validation of analytical methods used in bioavailability, bioequivalence, and pharmacokinetics studies in humans and animals.
Journal ArticleDOI
Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.
Check Y. Sum,Avraham Yacobi,Ronald Kartzinel,Herman F. Stampfli,Charles S Davis,Chii-Ming Lai +5 more
TL;DR: Esmolol was followed by a significant reduction of isoproterenol‐induced increase in heart rate and systolic blood pressure at doses of 50, 150, and 400 μg/kg/min, indicating that nonhepatic routes play a predominant role in its clearance.
Journal ArticleDOI
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
Carl C. Peck,William H. Barr,Leslie Z. Benet,Jerry M. Collins,Robert E. Desjardins,Daniel E. Furst,John G. Harter,Gerhard Levy,Thomas M. Ludden,John H. Rodman,Lilly Sanathana,Jerome J. Schentag,Vinod P. Shah,Lewis B. Sheiner,Jerome P. Skelly,Donald R. Stanski,Robert Temple,C. T. Viswanathan,Judi Weissinger,Avraham Yacobi +19 more
TL;DR: Clinical Pharmacology and Therapeutics (1992) 51, 465–473; doi:10.1038/clpt.1992.47